Back to Journals » Therapeutics and Clinical Risk Management » Volume 5

Parenteral clevidipine for the acute control of blood pressure in the critically ill patient: a review

Authors Peacock F, Angeles JE, Soto KM, Lumb PD, Varon J

Published 4 August 2009 Volume 2009:5 Pages 627—634

DOI https://doi.org/10.2147/TCRM.S5312

Review by Single-blind

Peer reviewer comments 5


W Frank Peacock IV1, Jorge E Angeles2, Karina M Soto2, Philip D Lumb3,  Joseph Varon4

1The Cleveland Clinic, Cleveland, OH, USA; 2Universidad Autónoma de Baja California, Facultad de Medicina, Tijuana, México; 3Keck School of Medicine of University of Southern California, Los Angeles, CA, USA; 4The University of Texas Health Science Center at Houston, and The University of Texas Medical Branch at Galveston. St. Luke’s Episcopal Hospital/Texas Heart Institute, Houston, Texas, USA

Abstract: Clevidipine is a new calcium channel blocker of the dihydropyridine class that is characterized by its ultra-short onset of action, vascular selectivity, small volume of distribution and extremely high clearance that coupled together result in an extremely short half-life of approximately 1 minute therefore permitting a rapid titration to the desired effect. Structurally similar to other dihydropyridines, clevidipine has an extra ester link that allows its rapid hydrolization to its inactive carboxylic acid metabolite in blood and extravascular tissues. Clevidipine’s metabolites are then primarily eliminated through urine and fecal pathways. Clevidipine does not affect cytochrome P450 (CYP) enzymes and no clinically significant drug interactions have been determined. In trials like the ESCAPE trials, ECLIPSE, and VELOCITY, clevidipine demonstrated a significant improvement in the management of acute hypertension when compared to placebo as shown in both ESCAPE trials. The ECLIPSE trial compared clevidipine to other drugs currently used in the management of acute hypertension, such as sodium nitroprusside, nitroglycerine and nicardipine; clevidipine was superior to all three agents; in providing blood pressure support, safety and tolerability clevidipine also showed a significant reduction in mortality rate (4.7% vs 1.7%, P = 0.0445) when compared to sodium nitroprusside. In the VELOCITY trial clevidipine demonstrated a reduction in blood pressure of 6% at the 3 minute mark, 15% within 9.5 minutes and 27% at the 18 hour mark.

Keywords: clevidipine, calcium channel blockers, hypertensive crisis, hypertensive emergency, hypertensive urgency.

General overview

The newest intravenous antihypertensive agents available to the clinician are reviewed. Clevidipine, a new arterial selective dihydropyridine calcium channel blocker with an ultra short onset of action and small volume of distribution, does not affect cytochrome P450 enzymes, exhibits no clinically significant drug interactions, and can be used in renal or hepatic failure. Metabolized by blood and extra-vascular tissues, its half life of approximately 1 minute permits rapid blood pressure control. In large trials clevidipine had better blood pressure control than other currently used drugs, and reduced mortality compared with nitroprusside. Finally, in the VELOCITY trial, clevidipine controlled blood pressure within a median of 11 minutes, with no clinically relevant overshoot, and did not require invasive pressure monitoring.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]